Our Pipeline: First-In-Class
Bicara has more than a platform: We have a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors, including a lead program that’s already in the clinic.
- PROGRAMDISCOVERYIND-ENABLINGPHASE 1PHASE 2PHASE 3
- BCA101 EGFR & TGFβ
monotherapy - BCA101 EGFR & TGFβ
combination with pembrolizumab - BCA300
- BCA202
- BCA400
We have taken a pragmatic approach to building our pipeline. We seek out a powerful biological rationale and strong potential to address significant unmet needs, which include patients who are refractory to immune checkpoint inhibitors and first-line targeted therapies.
Posters and Publications
Digital Presentations: First-in-human Phase I Study of the Bifunctional EGFR/TGFβ Fusion Protein BCA101 in Patients with EGFR-driven Advanced Solid Cancers
American Society of Clinical Oncology, June 2021
Our Lead Program: BCA101
First-in-class EGFR / TGFβ-trap bifunctional antibody
Epidermal growth factor receptor (EGFR), a protein expressed on the surface of several tumor types, is one of the most extensively validated tumor-associated antigens.
Monoclonal antibodies directed at EGFR suppress the proliferation of EGFR-driven tumor cells and restrict tumor growth and metastasis. Inhibiting EGFR alone is inadequate to achieve durable therapeutic responses. Our solution: Simultaneous inhibition of EGFR and TGFβ — a signaling molecule that promotes tumor growth in the presence of EGFR and that plays a key role in suppressing the immune response in the tumor microenvironment.
Our lead program is thus a dual-action bifunctional antibody that both inhibits EGFR and disables TGFβ directly at the site of the tumor. With this approach, we hope to achieve superior anti-tumor efficacy with an improved therapeutic window.
Phase 1/2 Clinical Study
We have rapidly activated a first-in-human, Phase 1/2 study of BCA101 in EGFR-driven tumors at leading institutions in the US and Canada.
This study evaluates both single-agent BCA101 and combination treatment with BCA101 plus pembrolizumab, an immune checkpoint inhibitor, in select EGFR-driven tumors.
For more information, please visit clinicaltrials.gov.
Enrolling trial sites
Houston, TX
New York, NY
Boston, MA
Toronto, ON
New York, NY
Pittsburgh, PA